---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-000069"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2022-01-03T23:59:59+00:00"
generated_at: "2026-06-27T21:29:51.094216+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma gets FDA Rare Pediatric Disease designation for IMX-110 in rhabdomyosarcoma

## Summary
- FDA granted Rare Pediatric Disease designation for IMX-110 to treat rhabdomyosarcoma, a life-threatening pediatric cancer.
- If approved, Immix may receive a Priority Review Voucher (PRV), historically sold for $67M to $350M, transferable to other companies.
- IMX-110 is currently in a Phase 1b/2a clinical trial and also has orphan drug designation for soft tissue sarcoma.
- Company believes IMX-110 targets all three components of the tumor micro-environment via its SMARxT platform.

## SEC filing metadata
- accession: 0001493152-22-000069
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2022-01-03T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315222000069/0001493152-22-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315222000069/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-000069
- JSON: https://secwatch.observer/filing/0001493152-22-000069.json
- Plain text: https://secwatch.observer/filing/0001493152-22-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.